Cargando…
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
BRCA1 splice isoforms Δ11 and Δ11q can contribute to PARP inhibitor (PARPi) resistance by splicing-out the mutation-containing exon, producing truncated, partially-functional proteins. However, the clinical impact and underlying drivers of BRCA1 exon skipping remain undetermined. We analyzed nine ov...
Autores principales: | Nesic, Ksenija, Krais, John J., Vandenberg, Cassandra J., Wang, Yifan, Patel, Pooja, Cai, Kathy Q., Kwan, Tanya, Lieschke, Elizabeth, Ho, Gwo-Yaw, Barker, Holly E., Bedo, Justin, Casadei, Silvia, Farrell, Andrew, Radke, Marc, Shield-Artin, Kristy, Penington, Jocelyn S., Geissler, Franziska, Kyran, Elizabeth, Zhang, Fan, Dobrovic, Alexander, Olesen, Inger, Kristeleit, Rebecca, Oza, Amit, Ratnayake, Gayanie, Traficante, Nadia, DeFazio, Anna, Bowtell, David D. L., Harding, Thomas C., Lin, Kevin, Swisher, Elizabeth M., Kondrashova, Olga, Scott, Clare L., Johnson, Neil, Wakefield, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055590/ https://www.ncbi.nlm.nih.gov/pubmed/36993400 http://dx.doi.org/10.1101/2023.03.20.23287465 |
Ejemplares similares
-
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
por: Ho, Gwo Yaw, et al.
Publicado: (2023) -
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018) -
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
por: Ho, Gwo Yaw, et al.
Publicado: (2022) -
Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023) -
Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
por: Drew, Yvette, et al.
Publicado: (2019)